These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 16684005)

  • 1. Total joint replacement in patients with inhibitors.
    Solimeno LP; Perfetto OS; Pasta G; Santagostino E
    Haemophilia; 2006 Jul; 12 Suppl 3():113-6. PubMed ID: 16684005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.
    Astermark J; Morado M; Rocino A; van den Berg HM; von Depka M; Gringeri A; Mantovani L; Garrido RP; Schiavoni M; Villar A; Windyga J;
    Haemophilia; 2006 Jul; 12(4):363-71. PubMed ID: 16834735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors.
    Scalone L; Mantovani LG; Mannucci PM; Gringeri A;
    Haemophilia; 2006 Mar; 12(2):154-62. PubMed ID: 16476090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
    Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
    Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery.
    Shapiro AD; Gilchrist GS; Hoots WK; Cooper HA; Gastineau DA
    Thromb Haemost; 1998 Nov; 80(5):773-8. PubMed ID: 9843170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A successful use of recombinant factor VIIa in a patient with inhibitors, for bilateral cataract operation and circumcision.
    Leblebisatan G; Sasmaz I; Antmen B; Kilinc Y; Sizmaz S; Yagmur M
    Haemophilia; 2006 Mar; 12(2):187-9. PubMed ID: 16476096
    [No Abstract]   [Full Text] [Related]  

  • 7. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.
    Mathias M; Khair K; Hann I; Liesner R
    Br J Haematol; 2004 May; 125(3):366-8. PubMed ID: 15086418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent improvements in the clinical treatment of coagulation factor inhibitors.
    Franchini M; Lippi G
    Semin Thromb Hemost; 2009 Nov; 35(8):806-13. PubMed ID: 20169517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elective orthopaedic surgery for inhibitor patients.
    Rodriguez-Merchan EC; Wiedel JD; Wallny T; Hvid I; Berntorp E; Rivard GE; Goddard NJ; Querol F; Caviglia H
    Haemophilia; 2003 Sep; 9(5):625-31. PubMed ID: 14511305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case studies: orthopaedic surgery in adult patients with haemophilia A with inhibitors.
    Goddard N
    Haemophilia; 2005 Nov; 11 Suppl 1():32-7. PubMed ID: 16219049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to manage invasive procedures in children with haemophilia.
    Ljung RC; Knobe K
    Br J Haematol; 2012 Jun; 157(5):519-28. PubMed ID: 22390160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia.
    Astermark J
    Haemophilia; 2006 Jul; 12 Suppl 3():52-60. PubMed ID: 16683997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Perioperative use of recombinant activated factor VII (rF VIIa) in a patient with hemophilia A having inhibitors].
    Kawasaki Y; Saeki N; Kawamoto M; Yuge O; Fujii T
    Masui; 2005 Aug; 54(8):926-8. PubMed ID: 16104555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A.
    Franchini M; Girelli D; Olivieri O; Castaman G; Lippi G; Poli G; Salvagno GL; Tagariello G; Giuffrida A; de Gironcoli M; Morfini M; Berntorp E; Gandini G
    Haemophilia; 2006 Jul; 12(4):448-51. PubMed ID: 16834751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Forum on: the role of recombinant factor VIII in children with severe haemophilia A.
    Franchini M; Coppola A; Molinari AC; Santoro C; Schinco P; Speciale V; Tagliaferri A
    Haemophilia; 2009 Mar; 15(2):578-86. PubMed ID: 19187188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined factor VIII and IX inhibitors in a non-haemophilic patient: successful treatment with immunosuppressive drugs.
    Carmassi F; Giannarelli C; De Giorgi A; De Negri F
    Haemophilia; 2007 Jan; 13(1):106-7. PubMed ID: 17212735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laboratory identification of factor inhibitors: the perspective of a large tertiary hemophilia center.
    Kershaw G; Jayakodi D; Dunkley S
    Semin Thromb Hemost; 2009 Nov; 35(8):760-8. PubMed ID: 20169512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors.
    Giangrande PL; Wilde JT; Madan B; Ludlam CA; Tuddenham EG; Goddard NJ; Dolan G; Ingerslev J
    Haemophilia; 2009 Mar; 15(2):501-8. PubMed ID: 19187194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prospective matched control study concerning the treatment and quality of life of hemophiliacs with inhibitors].
    Honda K; Nagao T; Kamiya T; Yoshioka A; Miyazaki T; Takeda T; Mori K; Fukutake K; Hanabusa H; Taki M; Mohri H; Miyama J; Takamatsu J; Kinoshita S; Shirahata A
    Rinsho Ketsueki; 1998 Jun; 39(6):416-21. PubMed ID: 9695668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimizing factor requirements for surgery without increased risk.
    Schulman S; Loogna J; Wallensten R
    Haemophilia; 2004 Oct; 10 Suppl 4():35-40. PubMed ID: 15479370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.